A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever
A high intermittent dose regimen (group A: 10 mg kg−1 on day 1, 5 mg kg−1 on days 3 and 6) was compared with standard dosing (group B: 3 mg kg−1 per day for 14 days) of liposomal amphotericin B (LAB) for empirical treatment of persistent febrile neutropenia. A total cumulative dose of 1275 mg (group A) and 2800 mg (group B) was administered. Infusion-related adverse drug events, mainly rigors/chills, occurred more frequently with group A (11/45, 24 % infusions) than with group B (12/201, 6 % infusions) (P=0.002), which extended the mean infusion time by 20 min (P=0.001). Creatinine levels were similar in the two regimens: the A : B ratio of the area under the curve for creatinine (AUCCREATININE) for days 2–7 was 1.09 (P=0.27) and for days 2–14 was 1.05 (P=0.51). Rises in creatinine were mild (clinical toxicity criteria 1) in all patients with elevations. Hypokalaemia tended to be less severe in group A with a lower proportion of hypokalaemic days [57/143 (39 %) vs 80/137 (58 %), P=0.21], a higher AUCPOTASSIUM (A : B ratio of 1.06, P=0.12), a lower proportion of patients with hypokalaemia at the end of study (10 vs 61 %, P=0.01) and fewer potassium-supplemented days [12/210 (6 %) vs 41/210 (19.5 %), P<0.1]. There were mildly elevated median levels of serum bilirubin, alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, which were similar for the two regimens and were usually associated with other co-existing co-morbid conditions. The AUC for these enzymes was also similar in the two groups. No patient had discontinuation of the study drug due to toxicity. Composite success was identical for each regimen (11/15 patients, 73 %). Three of the fifteen patients in group B and none in group A developed invasive fungal infections (IFIs). β-d-Glucan levels were similar in both groups for patients without an IFI [AUCGLUCAN of 362 and 683 (P=0.36) for groups A and B, respectively]. The rate of defervescence was similar for each regimen (P=0.75). This feasibility study suggests that a short intermittent high-dose course of 10/5/5 mg LAB kg−1 on days 1, 3 and 6 may be as safe and effective as a standard 14 day course of 3 mg kg−1 per day, with drug-acquisition cost savings and reduced drug exposure. A larger study is indicated for confirmation of this.
Adler-MooreJ. P.,
OlsonJ. A.,
ProffittR. T.2004; Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 54:1096–1102[CrossRef]
BatesD. W.,
SuL.,
YuD. T.,
ChertowG. M.,
SegerD. L.,
GomesD. R.,
DasbachE. J.,
PlattR.2001; Mortality and costs associated with amphotericin B therapy. Clin Infect Dis 32:686–693[CrossRef]
BekerskyI.,
FieldingR. M.,
DresslerD. E.,
LeeJ. W.,
BuellD. N.,
WalshT. J.2002; Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46:828–833[CrossRef]
CampM. J.,
WingardJ. R.,
GilmoreC. E.,
LinL. S.,
DixS. P.,
DavidsonT. G.,
GellerR. B.1998; Efficacy of low dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob Agents Chemother 42:3103–3106
ClarkA. D.,
McKendrickS.,
TanseyP. J.,
FranklinI. M.,
ChopraR.1998; A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 103:198–204[CrossRef]
CoiffierB.,
LepageE.,
BriereJ.,
HerbrechtR.,
TillyH.,
BouabdallahR.,
MorelP.,
Van Den NesteE.,
SallesG.other authors2002; CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242[CrossRef]
ColletteN.,
Van der AuweraP.,
MeunierF.,
LambertC.,
SculierJ. P.,
CouneA.1991; Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 27:535–548[CrossRef]
CordonnierC.,
MohtyM.,
FaucherC.,
VeyN.,
PautasC.,
RobinM.,
MahiL.,
RibaudP.2005; Safety of a weekly administration of 10 mg/kg of liposomal amphotericin B for antifungal prophylaxis in allogeneic stem-cell transplant and acute leukemia patients. In American Society of Hematology 47th Annual Meeting10–13December 2005 Atlanta, GA, USA: abstract 5346
CornelyO. A.,
MaertensJ.,
BresnikM.,
EbrahimiR.,
UllmannA. J.,
BouzaE.,
HeusselC. P.,
LortholaryO.,
RiegerC.other authors2007; Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiload Trial. Clin Infect Dis 44:1289–1297[CrossRef]
CoukellA. J.,
BrogdenR. N.1998; Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55:585–612[CrossRef]
DemartiniG.,
LequaglieC.,
Brega MessoneP. P.,
ScaglioneF.,
FraschiniF.2005; Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion. J Chemother 17:82–85[CrossRef]
De PauwB.,
WalshT. J.,
DonnellyJ. P.,
StevensD. A.,
EdwardsJ. E.,
CalandraT.,
PappasP. G.,
MaertensJ.,
LortholaryO.other authors2008; Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821[CrossRef]
EllisM. E.,
al-HokailA.,
ClinkH.,
PadmosA.,
ErnstP.,
SpenceD. G.,
TharpeW. N.,
HillierV. F.1992; Double blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 36:172–179[CrossRef]
EllisM.,
ShamoonA.,
GorkaW.,
ZwaanF.,
al-RamadiB.2001; Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis 32:E87–E89[CrossRef]
EllisM.,
HedstromU.,
al-RamadiB.,
AlizadehH.,
KristensenJ.,
KshirsagarS.,
BlaschkeT.,
StevensD.,
KlingsporL.,
PoughiasL.2007; Pharmacokinetics, efficacy of 3mg/kg/day vs 10mg/kg day 1, 5 mg/kg days 3 and 6 liposomal amphotericin B (Ambisome) in febrile neutropenia. In 8th Congress of the European Association for Clinical Pharmacology and Therapeutics 29 August–1 September 2007, Amsterdam, the Netherlands, abstract P257
EllisM.,
al-RamadiB.,
FinkelmanM.,
HedstromU.,
KristensenJ.,
Ali-ZadehH.,
KlingsporL.2008; Assessment of the clinical utility of serial β -d-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57:287–295[CrossRef]
ErikssonU.,
SeifertB.,
ScaffnerA.2001; Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. BMJ 322:579–582[CrossRef]
FaragS. S.,
RuppertA. S.,
MrozekK.,
MayerR. J.,
StoneR. M.,
CarrollA. J.,
PowellB. L.,
MooreJ. O.,
PettanatiM. J.other authors2005; Outcome of induction and post-remission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group study. J Clin Oncol 23:482–493
FrancisP.,
LeeJ. W.,
HoffmanA.,
PeterJ.,
FrancesconiA.,
BacherJ.,
ShelhamerJ.,
PizzoP. A.,
WalshT. J.1994; Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of brochoalveolar d-mannitol and serum galactomannan as markers of infection. J Infect Dis 169:356–368[CrossRef]
GarciaA.,
Adler-MooreJ.,
ProffittR.2000; Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob Agents Chemother 44:2327–2332[CrossRef]
GareyK. W.,
RegeM.,
PaiM. P.,
MingoD. E.,
SudaK. J.,
TurpinR. S.,
BeardenD. T.2006; Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25–31[CrossRef]
GoldbergE.,
Gafter-GviliA.,
RobenshtokE.,
LeiboviciL.,
PaulM.2008; Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer 44:2192–2203[CrossRef]
GubbinsP. O.,
PenzakS. R.,
PlostonS.,
McConnellS. A.,
AnaissieA.2002; Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 22:961–971[CrossRef]
HughesW. T.,
ArmstrongD.,
BodeyG. P.,
BowE. J.,
BrownA. E.,
CalandraT.,
FeldR.,
PizzoP. A.,
RolstonK. V. I.other authors2002; 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751[CrossRef]
KelseyS. M.,
GoldmanJ. M.,
McCannS.,
NewlandA. C.,
ScarffeJ. H.,
OppenheimB. A.,
MuftiG. J.1999; Liposomal amphotericin B (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind placebo-controlled study. Bone Marrow Transplant 23:163–168[CrossRef]
LeendersA. C.,
DaenenS.,
JansenR. L.,
HopW. C.,
LowenbergB.,
WijermansP. W.,
CornelissenJ.,
HerbrechtR.other authors1998; Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205–212[CrossRef]
MRC WPLA2006; Medical Research Council Acute Lymphoblastic Leukemia Trial XII (UKALL XII), version 4.1, February 2006. Joint Trial with Eastern Cooperative Group (ECOG) – E2993. Protocol for adults with ALL. Modified for intrathecal therapy and Philadelphia Positive ALLJuly 2002 Revised May 2005, February 2006 http://www.ctsu.ox.ac.uk/projects/leuk/ukall2003
MillsW.,
ChopraR.,
LinchD. C.,
GoldstoneA. H.1994; Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single centre experience of 133 episodes in 116 patients. Br J Haematol 86:754–760[CrossRef]
MoenM. D.,
Lyseng-WilliamsonK. A.,
ScottL. J.2009; Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361–392[CrossRef]
OlsonJ. A.,
Adler-MooreJ.,
SchwartzJ.,
JensenG.,
ProffittR.2006; Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine aspergillosis model. Antimicrob Agents Chemother 50:2122–2131[CrossRef]
PattersonT. F.,
KirkpatrickW. R.,
WhiteM.,
HiemenzJ. W.,
WingardJ. R.,
DupontB.,
RinaldiM. G.,
StevensD. A.,
GraybillJ. R. for the Aspergillus Study Group; 2000; Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore 79:250–260[CrossRef]
PenackO.,
SchartzS.,
MartusP.,
ReinwaldM.,
Schmidt-HieberM.,
ThielE.,
BlauI. W.2006; Low dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized single center trial. Ann Oncol 17:1306–1312[CrossRef]
PrenticeH. G.,
HannI. M.,
HerbrechtR.,
AounM.,
KvaloyS.,
CatovskyD.,
PinkertonC. R.,
ScheyS. A.,
JacobsF.other authors1997; A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711–718[CrossRef]
SmithP. J.,
OlsonJ. A.,
ConstableD.,
SchwartzJ.,
ProffittR. T.,
Adler-MooreJ.2007; Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 59:941–951[CrossRef]
SobelJ. D.2006; Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. Pharmacotherapy 26:47S–54S[CrossRef]
TakemotoK.,
YamamotoY.,
UedaY.,
SumitaY.,
YoshidaK.,
NikiY.2006a; Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 57:724–731[CrossRef]
TownsendR. W.,
ZutshiA.,
BeherskyI.2001; Biodistribution of 4-[14C]cholesterol–AmBisome following a single intravenous administration to rats. Drug Metab Dispos 29:681–685
VogelsingerH.,
WeilerS.,
DjananiA.,
KountchevJ.,
Bellmann-WeilerR.,
WiedermannC. J.,
BellmannR.2006; Amphotericin B distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 57:1153–1160[CrossRef]
WalshT. J.,
FinbergR. W.,
ArndtC.,
HiemenzJ.,
SchwartzC.,
BodensteinerD.,
PappasP.,
SeibelN.,
GreenbergR. N.other authors1999; Liposomal amphotericin B for empirical therapy in patients with persisting fever and neutropenia. N Engl J Med 340:764–771[CrossRef]
WalshT. J.,
GoodmanJ. L.,
PappasP.,
BekerskyI.,
BuellD. N.,
RodenM.,
BarrettJ.,
AnaissieA. J.2001; Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45:3487–3496[CrossRef]
WalshT. J.,
PappasP.,
WinstonD. J.,
LazarusH. M.,
PetersenF.,
RaffalliJ.,
YanovichS.,
StiffP.,
GreenbergR.other authors2002; Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234[CrossRef]
WalshT. J.,
TepplerH.,
DonowitzG. R.,
MaertensJ. A.,
BadenL. R.,
DmoszynskaA.,
CornelyO. A.,
BourqueM. R.,
LupinacciR. J.other authors2004; Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402[CrossRef]
WingardJ. R.,
WhiteM. H.,
AnaissieE.,
RaffalliJ.,
GoodmanJ.,
ArrietaA. L.2000; A randomized double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163[CrossRef]
A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever